NO20081807L - Kombinasjoner innbefattende en VEGF-reseptorinhibitor - Google Patents

Kombinasjoner innbefattende en VEGF-reseptorinhibitor

Info

Publication number
NO20081807L
NO20081807L NO20081807A NO20081807A NO20081807L NO 20081807 L NO20081807 L NO 20081807L NO 20081807 A NO20081807 A NO 20081807A NO 20081807 A NO20081807 A NO 20081807A NO 20081807 L NO20081807 L NO 20081807L
Authority
NO
Norway
Prior art keywords
vegf receptor
receptor inhibitor
combinations including
combinations
inhibitor
Prior art date
Application number
NO20081807A
Other languages
English (en)
Norwegian (no)
Inventor
Andreas Billich
Anton Stuetz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0518671A external-priority patent/GB0518671D0/en
Priority claimed from GB0518672A external-priority patent/GB0518672D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081807L publication Critical patent/NO20081807L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20081807A 2005-09-13 2008-04-14 Kombinasjoner innbefattende en VEGF-reseptorinhibitor NO20081807L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0518671A GB0518671D0 (en) 2005-09-13 2005-09-13 Organic compounds
GB0518672A GB0518672D0 (en) 2005-09-13 2005-09-13 Organic compounds
PCT/EP2006/008857 WO2007031265A2 (en) 2005-09-13 2006-09-12 Combinations comprising a vegf receptor inhibitor and a penetration enhancer

Publications (1)

Publication Number Publication Date
NO20081807L true NO20081807L (no) 2008-05-16

Family

ID=37663150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081807A NO20081807L (no) 2005-09-13 2008-04-14 Kombinasjoner innbefattende en VEGF-reseptorinhibitor

Country Status (23)

Country Link
US (2) US20080306058A1 (de)
EP (1) EP1945217B1 (de)
JP (1) JP2009507871A (de)
KR (1) KR20080058376A (de)
AR (1) AR056194A1 (de)
AT (1) ATE555790T1 (de)
AU (1) AU2006291526B2 (de)
BR (1) BRPI0615881A2 (de)
CA (1) CA2621399A1 (de)
EC (1) ECSP088259A (de)
GT (1) GT200600411A (de)
IL (1) IL189984A0 (de)
MA (1) MA29788B1 (de)
MY (1) MY145751A (de)
NO (1) NO20081807L (de)
NZ (1) NZ566474A (de)
PE (1) PE20070457A1 (de)
RU (1) RU2424804C2 (de)
SA (1) SA06270315B1 (de)
SG (1) SG165371A1 (de)
TN (1) TNSN08112A1 (de)
TW (1) TWI325321B (de)
WO (1) WO2007031265A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605120D0 (en) * 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CA2683049A1 (en) 2007-04-17 2008-10-23 Novartis Ag Organic compounds
BRPI0816239A2 (pt) * 2007-08-22 2015-02-24 Allergan Inc Derivados terapêuticos de quinolina e naftaleno
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
EP2661434A4 (de) * 2011-01-06 2014-07-09 Beta Pharma Canada Inc Neue harnstoffe zur behandlung und prävention von krebs
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
TWI611817B (zh) * 2011-12-01 2018-01-21 帝國製藥股份有限公司 含有羅匹尼羅（ｒｏｐｉｎｉｒｏｌｅ）之貼附劑
US9540381B2 (en) 2013-04-09 2017-01-10 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Anti-angiogenesis compound, intermediate and use thereof
EP3064489A4 (de) * 2013-11-01 2017-06-21 Ube Industries, Ltd. Aryloyl(oxy- oder amino-)pentafluorsulfanylbenzen-verbindung, pharmazeutisch unbedenkliches salz davon und prodrugs davon
EP3079683A4 (de) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung eines lymphoplasmazytischen lymphoms
CN104860885B (zh) 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
MX394560B (es) 2016-06-01 2025-03-24 Bayer Pharma AG Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales.
EP4112054A4 (de) * 2020-02-28 2024-03-27 Shanghai Runshi Medical Technology Co., Ltd Verwendung von csf-1r-kinasehemmer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
CA2381821A1 (en) * 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
NZ516582A (en) * 2000-06-01 2004-08-27 Watson Pharmaceuticals Inc Transdermal delivery of lasofoxifene
HK1054393B (en) * 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AU9598601A (en) * 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
CZ301310B6 (cs) * 2001-09-04 2010-01-13 Trommsdorff Gmbh & Co. Kg Arzneimittel Náplast
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
US20060004029A1 (en) * 2002-08-30 2006-01-05 Akihiko Tsuruoka Nitrogen-containing aromatic derivatives
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
MXPA06002256A (es) * 2003-08-29 2006-05-17 Pfizer Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos.
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
GEP20084439B (en) * 2004-01-23 2008-07-25 Amgen Inc Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
EP1568368A1 (de) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmazeutische Kombination enthaltend einen CDK Inhibitoren und einen VEGF Rezeptor Inhibitoren
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa

Also Published As

Publication number Publication date
EP1945217A2 (de) 2008-07-23
JP2009507871A (ja) 2009-02-26
TWI325321B (en) 2010-06-01
WO2007031265A3 (en) 2007-07-12
AU2006291526B2 (en) 2010-07-29
EP1945217B1 (de) 2012-05-02
SG165371A1 (en) 2010-10-28
TNSN08112A1 (en) 2009-07-14
RU2008114048A (ru) 2009-10-20
BRPI0615881A2 (pt) 2011-05-31
ATE555790T1 (de) 2012-05-15
TW200744600A (en) 2007-12-16
US20080306058A1 (en) 2008-12-11
AU2006291526A1 (en) 2007-03-22
MY145751A (en) 2012-03-30
ECSP088259A (es) 2008-04-28
PE20070457A1 (es) 2007-06-06
IL189984A0 (en) 2008-11-03
WO2007031265A2 (en) 2007-03-22
SA06270315B1 (ar) 2010-12-21
NZ566474A (en) 2011-05-27
KR20080058376A (ko) 2008-06-25
AR056194A1 (es) 2007-09-26
MA29788B1 (fr) 2008-09-01
GT200600411A (es) 2007-05-21
US20120172386A1 (en) 2012-07-05
RU2424804C2 (ru) 2011-07-27
CA2621399A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
NO20081807L (no) Kombinasjoner innbefattende en VEGF-reseptorinhibitor
EA200702643A1 (ru) Антитела, связывающие tweak
NO20053161D0 (no) Mikrobedrepende sammensetning.
JO3492B1 (ar) تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط nep
NO20082191L (no) Forbindelser
BRPI0811549A2 (pt) Inibidor de carepa à base de polissacarídeos.
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
ITMO20050009A1 (it) Apparato di serraggio.
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
NL2000273A1 (nl) Presentatie-inrichting.
NO20041865L (no) Pressbar sprengstoffkomposisjon
ATE496049T1 (de) Als monoamin wiederaufnahmehemmer geeignete 8- azabicycloä3.2.1üoctanderivate
NO20065283L (no) Avbarkingsmekanisme
NL1029306A1 (nl) Poolanker.
ITPN20050087A1 (it) Dispositivo tendifilo.
ITTV20050055A1 (it) Dispositivo luminoso.
NO20052107D0 (no) Rep.
NO20065284L (no) Avbarkingsmekanisme
FR2890529B1 (fr) Pailleuse robotisee.
DK1761221T3 (da) Fastgørelsesmekanisme til stomiposer
DE602004018483D1 (de) Fotopolymerisierbare Zusammensetzung.
ES1057788Y (es) Tapon de corcho.
BRPI0405373B1 (pt) carimbo portátil.
ES1057798Y (es) Grifo.
ES1060976Y (es) Llave de maniobra.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application